Nafoxidine

Nafoxidine, a nonsteroidal estrogen antagonist, is shown to possess antitumor activity against breast cancer.

Product Specifications

CAS Number

[1845-11-0]

Product Name Alternative

Nafoxidene

UNSPSC

12352005

Hazard Statement

H302+H312

Target

Estrogen Receptor/ERR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/nafoxidine.html

Purity

98.75

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

COC1=CC(CCC(C2=CC=CC=C2)=C3C4=CC=C(OCCN5CCCC5)C=C4)=C3C=C1

Molecular Formula

C29H31NO2

Molecular Weight

425.56

Precautions

H302+H312

References & Citations

[1]Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996;10 (8) :905-912. |[2]De Lorenzo MS, Farina HG, Alonso DF, Gomez DE. Role of protein kinase C-dependent signaling pathways in the antiangiogenic properties of nafoxidine. Anticancer Res. 2004;24 (3a) :1737-1743.|[3]Yaz G, Kabadere S, Oztopçu P, Durmaz R, Uyar R. Comparison of the antiproliferative properties of antiestrogenic drugs (nafoxidine and clomiphene) on glioma cells in vitro. Am J Clin Oncol. 2004;27 (4) :384-388.